Organization
Jiangsu Simcere Pharmaceutical
21 clinical trials
1 abstract
Clinical trial
An Open-Label, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in Non-Muscle-Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-26
Clinical trial
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Investigate the Pharmacokinetics, Safety, and Tolerability After Single- and Multiple-Dose Daridorexant in Chinese Healthy SubjectsStatus: Completed, Estimated PCD: 2023-12-24
Clinical trial
A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.Status: Active (not recruiting), Estimated PCD: 2023-12-08
Clinical trial
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Pharmacokinetics and Antitumor Activity of SIM0501 as Monotherapy and in Combination in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Single-center, Randomized, Double-blind, Sponsor Open, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 After Single and Multiple Subcutaneous Injections in Chinese Healthy SubjectsStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or TopotecanStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
A Phase I, First-in-Human, Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Subjects With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase I Study to Investigate The Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male ParticipantsStatus: Completed, Estimated PCD: 2022-08-07
Clinical trial
A Single Center, Non-randomized, Open-label Phase I Study to Investigate the Pharmacokinetics and Safety of SIM0417/Ritonavir After Single Dose Administration in Healthy Elderly SubjectsStatus: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world StudyStatus: Completed, Estimated PCD: 2022-04-10
Clinical trial
A Multicenter, Randomized, Double-blind, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
Randomized, Double-blind, Phase Ib Clinical Trial to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetic of SSD8432/ Ritonavir Multiple Doses in Treatment of Adults With Asymptomatic Infection, Mild, and Common Type of COVID-19Status: Completed, Estimated PCD: 2022-08-29
Clinical trial
A Multicenter, Non-randomized, Open-label, Parallel Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SIM0417/Ritonavir After a Single Dose in Subjects With Renal or Hepatic ImpairmentStatus: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Adult Chinese ParticipantsStatus: Completed, Estimated PCD: 2023-01-26
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, and PK Characteristics of SIM1910-09 After Single/Multiple Dosing in Healthy Chinese VolunteersStatus: Completed, Estimated PCD: 2023-03-23
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Efficacy of SIM0270 Alone or in Combination in Subjects With ER-positive, HER-2 Negative Locally Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Abstract
SCR-A002, a novel FGFR2b-targeting antibody-drug-conjugate for solid tumors.Org: State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China, Jiangsu Simcere Pharmaceutical,